Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 158-164

  Han, Kwang Hyub ^a   Kudo, Masatochi ^e   Ye, Sheng Long ^g   Choi, Jong Young ^b   Poon, Roonni Tung Ping ^h   Seong, Jinsil ^a   Park, Joong Won ^d   Ichida, Takafumi ^f   Chung, Jin Wook ^c   Chow, Pierce ⁱ   Cheng, Ann Lii ^j  

^a Yonsei University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d National Cancer Center   (South Korea)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^g ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Advanced stage; Diagnosis; Epidemiology; Hepatocellular carcinoma; Intermediate stage; Outcome; Staging system; Survival; Treatment

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ASIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ASIA; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; GUIDELINES AS TOPIC; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84855300819     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333280     Document Type: Conference Paper

References (30)

1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J: Cancer Incidence in Five Continents. Lyon, IARC, 2010.
2. Kudo M, Han KH, Kokudo N, et al: Liver Cancer Working Group Report. Jpn J Clin Oncol 2010;40(suppl 1):i19-i27.
3. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-524. (Pubitemid 34183954)
6. Forner A, Reig ME, de Lope CR, Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
7. Marrero JA, Kudo M, Bronowicki JP: The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 2010;15(suppl 4):23-33.
8. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, Chen CL, Chen TY, Huang YJ, Lu SN: The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - survival analysis of 3,892 patients. Eur J Cancer 2008;44:1000-1006.
9. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
10. Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference - European Association for the Study of the Liver. J Hepatol 2001;35:421-430. (Pubitemid 32844200)
11. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M: Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-922. (Pubitemid 46809293)
12. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405. (Pubitemid 39657014)
13. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score). J Gastroenterol 2003;38:207-215. (Pubitemid 36527122)
14. Kitai S, Kudo M, Minami Y, et al: Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging score, the conventional Japan Integrated Staging score and the BALAD score. Oncology 2008;75(suppl 1):83-90.
15. Han KH, Kim JK: Liver cancer in Korea. Hepatol Res 2007;37(suppl 2):S106-S109.
16. Han KH, Lee JT, Seong J: Treatment of non-resectable hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17(suppl 3):S424-S427. (Pubitemid 35454322)
17. Shim SJ, Seong J, Han KH, et al: Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189-1196. (Pubitemid 41782564)
18. Malagari K, Chatzimichael K, Alexopoulou E, et al: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008;31:269-280.
19. Poon RT, Tso WK, Pang RW, et al: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100-1108.
20. Varela M, Real MI, Burrel M, et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-481. (Pubitemid 46201723)
21. Lammer J, Malagari K, Vogl T, et al: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
22. Salem R, Lewandowski RJ, Mulcahy MF, et al: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64.
23. Kokudo N, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44(suppl 19):119-121.
24. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72:S2-S15.
25. Korean Liver Cancer Study Group and National Cancer Center, Korea: Practice guidelines for management of hepatocellular carcinoma 2009 (in Korean). Korean J Hepatol 2009;15:391-423.
26. Lee JM, Han KH: Positioning and indication of sorafenib in the treatment algorithm and real practice setting: western and eastern approach - Asian perspective. Oncology 2010;78(suppl 1):167-171.
27. Kudo M, Ueshima K: Positioning and indication of sorafenib in the treatment algorithm and real practice setting and implication of many complete remission cases in Japan. Oncology 2010;78(suppl 1):154-166.
28. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474.
29. Poon D, Anderson BO, Chen LT, et al: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-1118.
30. Yeo W, Chen PJ, Furuse J, Han KH, et al: Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620.